Key Market Indicator:
F&G: 49
25.158,75 NASDAQ · 49.141,50 DOW · 6.887,85 S&P · 4.825,03 Gold · 64,57 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© EQS Newswire
02.10.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Abspaltung der Pentixapharm AG im Handelsregister eingetragen
Article
News Preview
Berlin, 2.10.2024. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) informiert, dass der in der ordentlichen Hauptversammlung vom 26.6.2024 beschlossene Abspaltungsbeschluss am heutigen Tag in das Handelsregister des Amtsgerichts Charlottenburg (Berlin) eingetragen wurde. Mit der Eintragung in das Handelsregister der Eckert & Ziegler SE ......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.10.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Spin-off of Pentixapharm AG Registered with the Commercial Register
Article
News Preview
Berlin, 2 October 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pe......
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia completes analytical validation of its next-generation pancreatic cancer test
Article
News Preview
LUND, Sweden, Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation demonstrated excellent results across a comprehensive set...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
02.10.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia completes analytical validation of its next-generation pancreatic cancer test
Article
News Preview
LUND, Sweden, Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation demonstrated excellent results across a comprehensive set...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
01.10.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
Article
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 01.10.2024 / 17:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cer......
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
ISIN: GB00BN4HT335
Indivior PLC
INDV
LISTED
NASDAQ
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm
Article
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Indivior PLC (“Indivior” or “the Company”) (NASDAQ: INDV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2024
ISIN: BE0003766806
Ion Beam Applications SA
IBAB
LISTED
EURONEXT
IBA SA – NOTIFICATION TRANSPARENCE
Article
News Preview
 ...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2024
ISIN: GB00BMX86B70
Haleon PLC
HLN
LISTED
LSE
Haleon Announces Leadership Transition in Canada: Rupa Bahri to Depart, Christine Jakovcic Appointed as New General Manager
Article
News Preview
MISSISSAUGA, ON, Oct. 1, 2024 /CNW/ - Haleon, a global leader in consumer health, today announced the appointment of Christine Jakovcic as General Manager, Haleon Canada. This appointment follows Rupa Bahri stepping down after a distinguished 13-year career with the company to pursue other interests. Over the past six years, Rupa's leadership has...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
ISIN: CA23256X4075
Cybin Inc.
HELP
LISTED
NASDAQ
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
Article
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the appointment of senior clinical team leaders, Dr. Mirza Rahman as Senior Vice Presiden...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2024
ISIN: GB00B2425G68
Craneware PLC
CRW
LISTED
AIMX
The Craneware Group Announces Strategic Partnership with Microsoft, Featuring Three Innovative Solutions on the Microsoft Azure Marketplace
Article
News Preview
DEERFIELD BEACH, Fla., Oct. 1, 2024 /PRNewswire/ -- The Craneware Group™, a leader in healthcare financial performance and 340B management, is excited to announce a strategic partnership with Microsoft through agreements related to the Microsoft Azure cloud platform....
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
ISIN: US03168L1052
Amneal Pharmaceuticals Inc
AMRX
LISTED
NASDAQ
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
Article
News Preview
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and Metsera, Inc. (“Metsera”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that they have entered into a collaboration agreement to enable the eff...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2024
ISIN: ES0167733015
Oryzon Genomics SA
ORY
LISTED
BME
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
Article
News Preview
MADRID and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the receipt of the official meeting minutes from a recent End-of-Phase II meeting fo...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
30.09.2024
ISIN: NL0012169213
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN führt digitales PCR-System QIAcuityDx für klinische Tests in der Onkologie ein
Article
News Preview
Erweitert das Anwendungsspektrum für die erfolgreiche digitale PCR-Plattform QIAcuity durch Einführung in den klinischen Bereich in Nordamerika und der EU // Bietet absolute Quantifizierung, die für die präzise Überwachung seltener Targets in der klinischen Diagnostik unerlässlich ist // Steigert Laboreffizienz und reduziert Kosten mit einem All-in...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
ISIN: GB00BN4HT335
Indivior PLC
INDV
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)
Article
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming October 1, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024, inclusive (the “Class Period”). If you are a shar...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.09.2024
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Adjustment of growth guidance for 2024 and 2025
Article
News Preview
Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025  Düsseldorf, September 30, 2024 – Gerresheimer AG (ISIN: DE000A0LD6E6) is adjusting its growth guidance for 2024 and 2025 due to the significantly slower than expected market recovery 2024 and lower anticipated market growth in 2025 in the vial market. The guidance is also affected ......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.09.2024
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Anpassung der Wachstumsprognose für 2024 und 2025
Article
News Preview
Gerresheimer AG: Anpassung der Wachstumsprognose für 2024 und 2025 Düsseldorf, 30. September 2024 – Gerresheimer AG (ISIN: DE000A0LD6E6) passt seine Wachstumsprognose für 2024 und 2025 an. Hintergrund ist die deutlich langsamer als erwartete Markterholung 2024 und das niedriger als erwartete Marktwachstum 2025 im Markt für Injektionsfläschchen. D......
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
Article
News Preview
Company announcement – No. 46 / 2024...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Change in number of shares and votes in Immunovia AB (publ)
Article
News Preview
LUND, Sweden, Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of units resolved by the board of directors on 20 May 2024 and approved by the annual general meeting on 19 June 2024, as well as the directed issue of units to un...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Change in number of shares and votes in Immunovia AB (publ)
Article
News Preview
LUND, Sweden, Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of units resolved by the board of directors on 20 May 2024 and approved by the annual general meeting on 19 June 2024, as well as the directed issue of units to un...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
New number of shares and votes in Sobi
Article
News Preview
STOCKHOLM, Sept. 30, 2024 /PRNewswire/ -- As per 30 September 2024, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 356,000,049 shares. All shares are common shares. The total number of votes is 356,000,049. The increase in the number of shares and votes results from issues of 1,641,103 class C shares. The clas...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
New number of shares and votes in Sobi
Article
News Preview
STOCKHOLM, Sept. 30, 2024 /PRNewswire/ -- As per 30 September 2024, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 356,000,049 shares. All shares are common shares. The total number of votes is 356,000,049. The increase in the number of shares and votes results from issues of 1,641,103 class C shares. The clas...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Article
News Preview
Press Release // September 30, 2024 Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz) OtulfiTMreceived FDA approval for both subcutaneous and intravenous formulations, to treat the same conditions as Stelara®   Approval represents the third successful FDA approval for a Formycon biosimilar, two of them in ......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi erhalten FDA-Zulassung für FYB202/ OtulfiTM (Ustekinumab-aauz)
Article
News Preview
Pressemitteilung // 30. September 2024 Formycon und Fresenius Kabi erhalten FDA-Zulassung für FYB202/ OtulfiTM (Ustekinumab-aauz) Die FDA genehmigt FYB202/OtulfiTM sowohl für subkutane als auch für intravenöse Formulierungen und für alle Stelara®-Indikationen   Diese Zulassung ist die dritte erfolgreiche FDA-Zulassung für ein Biosimilar von Fo......
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2024
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
Orion’s near-term climate targets approved by the Science Based Targets initiative
Article
News Preview
ORION CORPORATIONPRESS RELEASE30 SEPTEMBER 2024 at 10.00 a.m. EEST...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
ISIN: GB00BN4HT335
Indivior PLC
INDV
LISTED
NASDAQ
INDV Deadline: Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Article
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, 2024, both dates inclusive (the “Class Period”). Indivior PLC is a pharmaceutical company. For more information, submi...
Themefolio
Profiler
Peergroup
© BusinessWire
27.09.2024
ISIN: US09609G2093
bluebird bio, Inc.
BLUE
LISTED
NASDAQ
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
Article
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) with the Securities and Exchange Commission (“SEC”). With the completion of this filing, the Company is now current in its SEC periodic reporting obligations. About bluebird bio, Inc....
Themefolio
Profiler
Peergroup
© EQS Newswire
27.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz) Planegg-Martinsried, Germany, September 27, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the U.S. Food and Drug Administration (“FDA”) today approved FYB202/OtulfiTM......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA erteilt Zulassung für Stelara® - Biosimilar FYB202/Otulfi™ (Ustekinumab-aauz)
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 FDA erteilt Zulassung für Stelara®- Biosimilar FYB202/Otulfi™ (Ustekinumab-aauz) Planegg-Martinsried, Deutschland, 27. September 2024 – Die Formycon AG (FWB: FYB, “Formycon“) gibt bekannt, dass die U.S. Food and Drug Administration („FDA“) heute die Zulass......
Themefolio
Profiler
Peergroup
© Globe Newswire
27.09.2024
ISIN: US52490G1022
Legend Biotech Corp
LEGN
LISTED
NASDAQ
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
Article
News Preview
SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS...
Themefolio
Profiler
Peergroup
© PR Newswire
27.09.2024
ISIN: SE0000135485
RaySearch Laboratories AB (publ)
RAY B
LISTED
STO
RaySearch's CEO sells shares - remains a long-term shareholder
Article
News Preview
STOCKHOLM, Sept. 27, 2024 /PRNewswire/ -- RaySearch's founder and CEO, Johan Löf, has sold 150,000 Class B shares in RaySearch Laboratories AB (publ) on September 24, 2024. Johan Löf remains a long-term shareholder and after the transaction owns 5,443,084 Class A shares and 68,393 Class B shares, corresponding to 16.1 percent of the total number...
Themefolio
Profiler
Peergroup
© BusinessWire
27.09.2024
ISIN: IE0005711209
ICON PLC
ICLR
LISTED
NASDAQ
ICON plc Schedules Third Quarter 2024 Earnings Conference Call
Article
News Preview
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2024 after the market closes on Wednesday, October 23, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Th...
Themefolio
Profiler
Peergroup
© PR Newswire
27.09.2024
ISIN: SE0000135485
RaySearch Laboratories AB (publ)
RAY B
LISTED
STO
Latest innovations in RayStation, RayCare, and RayIntelligence to be presented at ASTRO 2024
Article
News Preview
STOCKHOLM, Sept. 27, 2024 /PRNewswire/ -- RaySearch will be exhibiting its latest software innovations at ASTRO in Washington, D.C., September 29 – October 1. Participants can book demonstrations of RayStation®* treatment planning system, RayCare®* oncology information system, and the cloud-based oncology analytics system RayIntelligence® in RayS...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Article
News Preview
Press Release // September 27, 2024Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases FYB202/Otulfi® received European Commission (EC) approval for both subcutaneous and intravenous formulations, providing a high-quality treatment option for European......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi erhalten Zulassung der Europäischen Kommission für FYB202/Otulfi® (Ustekinumab) zur Behandlung schwerwiegender inflammatorischer Erkrankungen
Article
News Preview
Pressemitteilung // 27. September 2024 Formycon und Fresenius Kabi erhalten Zulassung der Europäischen Kommission für FYB202/Otulfi® (Ustekinumab) zur Behandlung schwerwiegender inflammatorischer Erkrankungen FYB202/Otulfi® hat die Zulassung der Europäischen Kommission (EC) für subkutane und für intravenöse Formulierungen erhalten und bietet euro......
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Article
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
Article
News Preview
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update...
Themefolio
Profiler
Peergroup
© PR Newswire
26.09.2024
ISIN: DE0005313704
Carl Zeiss Meditec AG
AFX
LISTED
XETR
ZEISS reinvents lens extraction with the first hand-held ultrasound-free lens removal device, available in the U.S.
Article
News Preview
The ZEISS MICOR 700 uses the ZEISS NULEX (non-ultrasonic lens extraction) procedure to help surgeons broaden their intraocular working space, minimizing risk to surrounding eye structures and increasing operating room efficiency. DUBLIN, Calif. and JENA, Germany, Sept. 26, 2024 /CNW/ -- ZEISS Medical Technology today announced the broad U.S. dist...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic Upgrades its Financial Guidance for 2024
Article
News Preview
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
Article
News Preview
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in Africa impacted by the mpox outbreak....
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
Article
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda’s oncology research and development efforts....
Themefolio
Profiler
Peergroup
© EQS Newswire
26.09.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma, Gerresheimer und Stevanato Group schließen strategische 'Allianz für RTU'
Article
News Preview
SCHOTT Pharma, Gerresheimer und Stevanato Group schließen strategische "Allianz für RTU" Marktakzeptanz von „Ready-to-Use“-Primärverpackungen schreitet voran Verbesserung der Betriebseffizienz in pharmazeutischen Herstellungsprozessen Erhöhung der Patientensicherheit durch hochwertige sterile Primärverpackungen SCHOTT Pharma AG & Co. KGaA (M......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.09.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU”
Article
News Preview
SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU” Market advances adoption of ready-to-use containers Improved operational efficiency in pharmaceutical manufacturing processes Increased patient safety with high-quality sterile primary packaging SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), a pioneer ......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.09.2024
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Gerresheimer, Stevanato Group und SCHOTT Pharma schließen strategische 'Alliance for RTU'
Article
News Preview
Gerresheimer, Stevanato Group und SCHOTT Pharma schließen strategische "Alliance for RTU" Marktakzeptanz von „Ready-to-Use“-Primärverpackungen schreitet voran Verbesserung der Betriebseffizienz in pharmazeutischen Herstellungsprozessen Erhöhung der Patientensicherheit durch hochwertige sterile Primärverpackungen Düsseldorf, 26. September 2024. ......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.09.2024
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU”
Article
News Preview
Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU”  Market advances adoption of ready-to-use containers Improved operational efficiency in pharmaceutical manufacturing processes Increased patient safety with high-quality sterile primary packaging Düsseldorf, September 26, 2024. Gerresheimer AG (MDAX: G......
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
ISIN: IE000LK2BOB4
Mural Oncology PLC
MURA
LISTED
NASDAQ
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
Article
News Preview
Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
Article
News Preview
ORION CORPORATION INVESTOR NEWS 26 SEPTEMBER 2024 at 11.00 EEST...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.09.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec und Novo Nordisk gehen Technologiepartnerschaft für Zelltherapien der nächsten Generation ein
Article
News Preview
  Novo Nordisk stellt finanzielle Mittel für die Technologieentwicklung bei Evotec zur Verfügung, um die klinische und kommerzielle Herstellung von stammzellbasierten Therapien zu unterstützen   Hamburg, 26. September 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute bekannt, da......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.09.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
Article
News Preview
  Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies   Hamburg, Germany, 26 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a techn......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.09.2024
ISIN: GB0034330679
CelLBxHealth plc
CLBX
LISTED
AIMX
Angle PLC Announces 100th Publication Supporting Parsortix System Use
Article
News Preview
GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repairANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.09.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Article
News Preview
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technolog...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.09.2024
ISIN: GB0034330679
CelLBxHealth plc
CLBX
LISTED
AIMX
Angle PLC Announces Half-year Report
Article
News Preview
Interim Results for the six months ended 30 June 2024LARGE PHARMA STRATEGY IMPLEMENTED SUCCESSFULLYThree Large Pharma contracts secured each with substantial revenue potentialStrategic decision post period end to focus resources on pharma services GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / ANGLE plc ("ANGLE" or "the Compan...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2024
ISIN: NL0012169213
Qiagen NV
QGEN
LISTED
NYSE
PreAnalytiX, ein Joint Venture von QIAGEN und BD, bringt neuartige Lösung für urinbasierte Flüssigbiopsie auf den Markt
Article
News Preview
Das PAXgene Urine Liquid Biopsy Set mit Sammelbehälter und Nukleinsäure-Stabilisierungsröhrchen ermöglicht eine nicht-invasive Probenentnahme und direkte Stabilisierung zellfreier DNA aus Urin // QIAGEN vermarktetet das Set mit dem ersten verifizierten, standardisierten und vollständigen präanalytischen Workflow von der Urinsammlung über die Stabil...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2024
ISIN: GB00BYMT0J19
LivaNova PLC
LIVN
LISTED
NASDAQ
LivaNova to Announce Third-Quarter 2024 Results
Article
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release its third-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova....
Themefolio
Profiler
Peergroup
© PR Newswire
25.09.2024
ISIN: US2290503075
Cryoport Inc
CYRX
LISTED
NASDAQ
SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices
Article
News Preview
NASHVILLE, Tenn. and RANCHO CORDOVA, Calif., Sept. 25, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and SK pharmteco, a global contract development and manufacturing organization, today announced a strategic collaboration to provide fully integrated logi...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2024
ISIN: US8793691069
Teleflex Inc
TFX
LISTED
NYSE
Teleflex™ Chooses o9’s AI-Powered Platform for End-to-End Integrated Business Planning and Supply Chain Management
Article
News Preview
o9, a leading enterprise AI software platform provider for transforming planning and decision-making, today announced that Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has selected o9 to help enhance its end-to-end integrated business planning and supply chain management capabilities. This partnership inclu...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2024
ISIN: DK0060448595
Coloplast A/S
COLO B
LISTED
CPH
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Article
News Preview
Please see enclosed pdf....
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2024
ISIN: ES0157097017
Almirall SA
ALM
LISTED
BME
New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis
Article
News Preview
More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clearance with monthly maintenance dosing. Almirall S.A. (BME: ALM) announced these new long-...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2024
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
Article
News Preview
ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST          ...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2024
ISIN: FR0014000MR3
Eurofins Scientific SE
ERF
LISTED
EURONEXT
Eurofins CDMO Alphora Inc. Announces Construction of GMP Biologics Manufacturing Facility
Article
News Preview
Eurofins CDMO Alphora Inc. announces the construction of a new GMP Biologics manufacturing facility in Mississauga, Ontario, to manufacture monoclonal Antibodies (mAbs) and protein therapies for clinical and commercial applications. This investment has been complemented with substantial support from the Federal Government of Canada, and a contrib...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2024
ISIN: CA23256X4075
Cybin Inc.
HELP
LISTED
NASDAQ
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Article
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Amir Inamdar, Cybin’s Chief Medical Officer, will participate in a panel disc...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Wednesday, 21.01.2026, Calendar Week 04, 21st day of the year, 344 days remaining until EoY.